ADAM BIUCKIANS: Open Payments
NPI 1558342402 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,132 in 58 payments from 9 companies in 2025. Trend: 2023 $1,395 · 2024 $1,083 · 2025 $1,132
Food & beverage: $1,030Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $387 |
| Supernus Pharmaceuticals, Inc. | 13 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $215 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 1 | $37 |
| Alkermes, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
Products named: Qelbree, CAPLYTA, UZEDY, AUSTEDO XR, ABILIFY ASIMTUFII, INGREZZA, REXULTI, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
